NEW YORK, July 19, 2006 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA - News) today announced that Alan G. Harris, MD, PhD, chief medical officer, will present a scientific overview of oral Oleoyl-estrone (OE), the company's product candidate in development for the treatment of obesity, at the 2nd Annual Obesity Drug Development Summit. The summit is being held July 27-28, 2006 at the Ritz-Carlton in Tyson's Corner, VA; Dr. Harris' presentation will take place on Thursday, July 27 from 10:10am -- 10:40am EDT. OE is currently being tested in a Phase IIa clinical trial in Switzerland.
